AVA report growing number of unusual illness

BHA Revises Ringworm Rules

BHA Detection Times for Clenbuterol and Ipratropium

Practice Benchmarking Offer

AHS reported to be killing up to 400 horses a day

BEVA member's can now get 5% discount on selected SEIB insurance policies

Following the positive result of a precautionary test on the Cheltenham bound Binocular the BHA’s Tim Morris has reassured BEVA that there has been no change in testing sensitivities.  He is not advising vets to change the standard c7day withdrawal period “where a single IV injection of Dexamethasone Sodium Phosphate is administered at the standard dose rate”.   Prof. Morris states “We are rigorous in how we change lab levels, it's a formal process with a long lead in time when we inform vets. For example next Monday the board will be asked to approve Detection Times for clenbuterol and Ipratropium, which we have to do before any change, and we then we must do an education campaign and lead-in for several months.”   Prof. Morris has acknowledged that the lack of Detection Times for steroids is an issue.  He has commented that the previous HKJC advised detection periods / the old Jockey Club “red book” should not be relied upon – and has pointed those treating racehorses towards The European Horserace Scienti ...

Merck and sanofi-aventis announced today the mutual termination of their agreement to form a new animal health joint venture by combining Merial, the animal health business of sanofi-aventis, with Intervet/Schering-Plough, Merck's animal health unit. As a result, each party will keep its current, separate animal health assets and businesses. Since the initial announcement about the intended combination on March 9, 2010, both companies have worked diligently to create the proposed animal health joint venture, including submitting requests for the required antitrust reviews. The companies are discontinuing their agreement primarily because of the increasing complexity of implementing the proposed transaction, both in terms of the nature and extent of the anticipated divestitures and the length of time necessary for the worldwide regulatory review process. Merck and sanofi-aventis mutually determined that ending their plan is in the best interests of both companies and their respective shareholders, as well as t ...

Book your trade stand at Liverpool now!!!